Dirk Elston is a Dermatology physician affiliated with Medical University of South Carolina. OpenAlex indexes 883 publications with 8,992 citations (h-index 40); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
171 Ashley Ave
Charleston, SC 294258908
Telephone
843-792-1414Registry record last updated 8 Apr 2015.
Clinical trials
- DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone
Sponsor: Medical University of South Carolina
- Spironolactone for Hidradenitis Suppurativa
Sponsor: Medical University of South Carolina
- Spironolactone for the Treatment of Melasma
Sponsor: Medical University of South Carolina
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20245 payments
- UCB, Inc.Program year20242 payments
- Verrica Pharmaceuticals Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
29%Porphyrin Precursor7%Aminolevulinic acid hcl100%Part B, office-administered≥118 patientsInterleukin-23 Antagonist4.1%Skyrizi Pen60%Tremfya25%Skyrizi15%Part D<11 patients+ 9 more classes in this area
Dermatology
22.7%Interleukin-4 Receptor alpha Antagonist13.9%Dupixent Pen62%Dupixent Syringe39%Part D≥24 patientsCorticosteroid6.3%Triamcinolone acetonide52%Triamcinolone Acetonide48%Part D + Part B≥34 patients+ 2 more classes in this area
Cardiovascular
15.1%Arteriolar Vasodilator6.9%Minoxidil100%Part D≥49 patientsAldosterone antagonist (MRA)4.1%Spironolactone100%Part D≥35 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Participation bias, self-selection bias, and response bias
Journal of the American Academy of Dermatology
2021 - Perifollicular inflammation and follicular spongiosis in androgenetic alopecia
Journal of the American Academy of Dermatology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Tanya Turan, MD
Medical University of South Carolina
Michael Zile, MD
Medical University of South Carolina
Don Rockey, MD
Medical University of South Carolina
Katherine Ruzhansky, MD
Medical University of South Carolina
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”